Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention

• Type of Material: Article
• Authors: Wendy Landier, University of Alabama Birmingham; Smita Bhatia, University of Alabama Birmingham; Jpshua S Richman, University of Alabama Birmingham; Paula DC Gonzalez, University of Alabama Birmingham; Brooke Cherven, Emory University; Veronica Chollette, National Cancer Institute, Rockville; Jamie Aye, University of Alabama Birmingham; Sharon Castellino, Emory University; Maria M Gramatges, Baylor College of Medicine; Susan Lindemulder, Oregon Health & Science University; Thomas B Russell, Wake Forest University; Lucie M Turcotte, University of Minnesota, Minneapolis; Graham A Colditz, Washington University in St. Louis; Melissa B Gilkey, University of North Carolina; James Klosky, Emory University
• Language: English
• Date: 2022-09-12
• Publisher: BMC
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2022
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s12887-022-03562-1
• Title of Journal or Parent Work: BMC PEDIATRICS
• Volume: 22
• Issue: 1
• Start Page: 541
• End Page: 541
• Grant/Funding Information: This research is funded by a cooperative agreement from the National Cancer Institute; www.cancer.gov (U01CA246567; PIs WL and JLK). The contents are solely the responsibility of the authors and do not represent official views of, nor endorsement, by the National Cancer Institute or other federal agencies.
• Keywords: Vaccination rates; IMPACT; COMMUNICATION; Life Sciences & Biomedicine; RISK; UNITED-STATES; Human papillomavirus; IMMUNOGENICITY; REMINDER/RECALL; CHILDREN; Science & Technology; IMMUNIZATION RATES; Cluster-randomized trial; Childhood cancer survivors; ADOLESCENTS; Pediatrics; ADVISORY-COMMITTEE
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Background: Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). HPV vaccination is effective in preventing the infections that lead to these cancers, but HPV vaccine uptake is low among young cancer survivors. Lack of a healthcare provider recommendation is the most common reason that cancer survivors fail to initiate the HPV vaccine. Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on enhancing healthcare provider skills to effectively recommend the vaccine, and reducing barriers faced by the young people and their parents in receiving the vaccine. This study will evaluate the effectiveness and implementation of an evidence-based healthcare provider-focused intervention (HPV PROTECT) adapted for use in pediatric oncology clinics, to increase HPV vaccine uptake among cancer survivors 9 to 17 years of age. Methods: This study uses a hybrid type 1 effectiveness-implementation approach. We will test the effectiveness of the HPV PROTECT intervention using a stepped-wedge cluster-randomized trial across a multi-state sample of pediatric oncology clinics. We will evaluate implementation (provider perspectives regarding intervention feasibility, acceptability and appropriateness in the pediatric oncology setting, provider fidelity to intervention components and change in provider HPV vaccine-related knowledge and practices [e.g., providing vaccine recommendations, identifying and reducing barriers to vaccination]) using a mixed methods approach. Discussion: This multisite trial will address important gaps in knowledge relevant to the prevention of HPV-related malignancies in young cancer survivors by testing the effectiveness of an evidence-based provider-directed intervention, adapted for the pediatric oncology setting, to increase HPV vaccine initiation in young cancer survivors receiving care in pediatric oncology clinics, and by procuring information regarding intervention delivery to inform future implementation efforts. If proven effective, HPV PROTECT will be readily disseminable for testing in the larger pediatric oncology community to increase HPV vaccine uptake in cancer survivors, facilitating protection against HPV-related morbidities for this vulnerable population. Trial registration: ClinicalTrials.gov Identifier: NCT04469569, prospectively registered on July 14, 2020.